155098-65-0

Basic information

• Product Name: 4-(4-oxocyclohexyl)phenyl trifluoromethanesulfonate
• Synonyms: 4-(4-oxocyclohexyl)phenyl trifluoromethanesulfonate
• CAS NO: 155098-65-0
• Molecular Weight: 322.305
• Mol File: 155098-65-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(4-oxocyclohexyl)phenyl trifluoromethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-oxocyclohexyl)phenyl trifluoromethanesulfonate(155098-65-0)
• EPA Substance Registry System: 4-(4-oxocyclohexyl)phenyl trifluoromethanesulfonate(155098-65-0)

Safety Data

• Hazardous Substances Data: 155098-65-0(Hazardous Substances Data)

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 105640-07-1 4-(4-hydroxyphenyl)cyclohexan-1-one 

Downstream Products

• 1335151-12-6 methyl 4-(4,4-dihydroperoxycyclohexyl)benzoate 
• 137464-98-3 4-(4-oxocyclohexyl)benzoic acid methyl ester 
• 14472-80-1 4-(4-chlorophenyl)cyclohexan-1-one 
• 1374338-80-3 1-{6-[4'-(4,4-difluorocyclohexyl)-4-methylbiphenyl-2-yl]pyridin-2-yl}-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria

A series of aryl carboxamide and benzylamino dispiro 1,2,4,5-tetraoxane analogues have been designed and synthesized in a short synthetic sequence from readily available starting materials. From this series of endoperoxides, molecules with in vitro IC50s versus Plasmodium falciparum (3D7) as low as 0.84 nM were identified. Based on an assessment of blood stability and in vitro microsomal stability, N205 (10a) was selected for rodent pharmacokinetic and in vivo antimalarial efficacy studies in the mouse Plasmodium berghei and Plasmodium falciparum Pf3D70087/N9 severe combined immunodeficiency (SCID) mouse models. The results indicate that the 4-benzylamino derivatives have excellent profiles with a representative of this series, N205, an excellent starting point for further lead optimization studies.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.